Buy or sell Veritas Genetics stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Veritas Genetics Stock
Genetic testing platform
About Veritas Genetics Stock
Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer. The company's genetic technology can detect a wider range of variations in a gene than are typically found in next-generation sequencing and offers a screening test for hereditary breast and ovarian cancer risk, enabling clinical researchers and physicians in order to make informed decisions.
Investors
Lilly Asia Ventures
Philab Holdings Corp
Simcere Pharma
Funding History
| June 2015 | $12.0M |
|---|---|
| October 2016 | $30.0M |
| January 2018 | $4.6M |
| February 2018 | $500M |
Management
Co-Founder & Chief Executive Officer
Mirza Cifric
Co-Founder & Managing Director, Asia
Jonathan Zhao
Chief Commercial Officer & General Counsel
Douglas Flood
Press
Veritas Is Working to Bring Next Generation Sequencing Based COVID Testing at Scale and Improve Accessibility for Return to Work Initiatives
businesswire - Jul, 20 2020
Veritas Genetics, the start-up that can sequence a human genome for less than $600, ceases US operations and is in talks with potential buyers
CNBC - Dec, 5 2019
Veritas Now Provides Whole Genome Sequencing and Interpretation for Less Than 1,000€
prnewswire - Jul, 24 2019
George Church’s genetics on the blockchain startup just raised $4.3 million from Khosla
TechCrunch - Aug, 29 2018
30. Veritas Genetics
CNBC - May, 22 2018
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
